Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • Medical Jobs
  • Medical Matrimony
  • MD Brand Connect
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • MCI News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Aborad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • MCI News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • News
  • Industry
  • Pharma News
  • Provide more safety,...

Provide more safety, immunogenicity data: CDSCO panel tells Biological E on trial of COVID vaccine

Medical Dialogues TeamWritten by Medical Dialogues Team Published On 2021-08-03T15:50:08+05:30  |  Updated On 3 Aug 2021 10:20 AM GMT
Provide more safety, immunogenicity data: CDSCO panel tells Biological E on trial of COVID vaccine

New Delhi: Following the proposal presented by Biological E to conduct a Phase II/III clinical trial of its Covid-19 vaccine containing the SARSCoV-2 Receptor Binding Domain of SARSCoV-2 in the age group of 5 years to 17 years, the Subject Expert Committee (SEC) functional under the Central Drug Standard Organization (CDSCO) has recommended Hyderabad-based vaccine-maker to submit safety...

New Delhi: Following the proposal presented by Biological E to conduct a Phase II/III clinical trial of its Covid-19 vaccine containing the SARSCoV-2 Receptor Binding Domain of SARSCoV-2 in the age group of 5 years to 17 years, the Subject Expert Committee (SEC) functional under the Central Drug Standard Organization (CDSCO) has recommended Hyderabad-based vaccine-maker to submit safety and immunogenicity data from Phase II part of the Phase II/III clinical trial in adults to the CDSCO.

This came in response to the proposal presented by Hyderabad-based vaccine-maker, Biological E, for the grant of permission to conduct a Phase II/III clinical trial of Covid-19 vaccine containing the SARSCoV-2 Receptor Binding Domain of SARSCoV-2 in the age group of 5 years to 17 years, along with interim safety and immunogenicity data (after dose 1) from the ongoing Phase-II/III clinical trial in adults with revised composition.

Corbevax, also known as BioE COVID-19, is a COVID-19 vaccine candidate developed by Biological E. Limited (BioE), Baylor College of Medicine in Houston, Texas, and Dynavax Technologies in the United States (DVAX). The vaccine candidate includes an antigen in-licensed from BCM Ventures, Baylor College of Medicine's integrated commercialization team, along with Dynavax's advanced adjuvant CpG 1018.

Also Read: Biological E to supply 30 crore COVID vaccine doses to Centre

Corbevax is a recombinant protein subunit vaccine that contains the Receptor Binding Domain of the SARS-CoV-2 Spike Protein. It simply injects the virus's spike protein into the human body in order to trigger an immunological response. When the virus attacks the body after the vaccine is administered, the body will already have an immune response in place to protect the individual against fatal illnesses.

At the 169th SEC meeting regarding examining COVID-19 related proposals under the accelerated approval process held on 29.07.2021 at CDSCO, Biological E's proposal to conduct a Phase II/III clinical trial of its Covid-19 vaccine containing SARSCoV-2 Receptor Binding Domain of SARSCoV-2 in the age group of 5 years to 17 years was thoroughly examined by the committee.

In this regard, the committee noted that the vaccine is under Phase II/III clinical trial in the age group ≥ 18 years of age and full safety and immunogenicity data is not ready for assessment.

After detailed deliberation, the committee recommended that

1. Safety and immunogenicity data from Phase II part of the Phase II/III clinical trial in adults to be submitted to CDSCO.

2. The clinical trial protocol should be revised as follows:

i. The study design should be revised to be a double-blind, placebo-controlled non-inferiority study and the noninferiority margin should be as per WHO guidelines.

ii. The safety data of the first 100 participants in the age group of 12-18 years should be evaluated by the Data and Safety Monitoring Board (DSMB) and the results submitted to CDSCO before proceeding to phase-III part.

Accordingly, the committee further directed the firm to submit the revised clinical trial protocol along with data for further review by the committee.

Also Read: Biological E expects to launch COVID vaccine Corbevax by September end: Sources

biological e corbevax covid 19 cdsco sec committee covid vaccine who 
Medical Dialogues Team
Medical Dialogues Team

    Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.

    Show Full Article
    Next Story
    Similar Posts
    NO DATA FOUND

    Editorial

    Journal Club Today

    Health News Today

    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    X